Prognose

Analytikernes gennemsnitlige kursmål er 4,31 € (+64,50 %). Medianen er 4,31 € (+64,50 %).

Køb	6
Behold	1
Sælg	0

Nyheder Til nyhedsfeedet

Neuronetics reports Q2 2026 revenue growth, narrows guidance and advances toward profitability

Neuronetics posted Q2 revenue of $41.6 million, up ~9% year-over-year, driven by Greenbrook clinics ($26.9 million, +16.8%) while NeuroStar revenue declined to $14.7 million as the company shifts customers from a session model toward capital sales and leasing. Gross margin improved to 51.1% and adjusted EBITDA was positive $0.3 million, with net loss narrowing to $3.4 million; cash totaled $25 million at quarter end after $7.6 million raised via an ATM. Management narrowed full-year revenue guidance to $160–164 million, lowered OPEX guidance and expects reduced cash burn as it scales Greenbrook, rolls out new NeuroStar commercial options and pursues interventional psychiatry opportunities. » Mere på finance.yahoo.com
Neuronetics: stock jumps after strong quarterly results and turnaround hopes

For Q2 2026 Neuronetics reported revenue of $41.6 million (+9.1% y/y) and a net loss of $3.4 million (‑$0.05 per share), markedly better than the consensus estimate of about ‑$0.12. The clinic segment Greenbrook contributed $26.9 million (+16.8%) and was a key driver of growth; adjusted EBITDA improved to $0.3 million versus ‑$5.6 million a year earlier, and the cash outflow from operating and investing activities fell to $1.4 million. Management changes, including a new CFO, boosted confidence in the turnaround strategy, after which the stock rose about 24% in premarket trading. » Mere på de.investing.com
Neuronetics amends adviser agreement for interim principal financial and accounting officer and raises monthly compensation

Neuronetics has revised the adviser agreement with interim Principal Financial and Accounting Officer Francis X. Brown III effective May 18, 2026; Brown will remain in office until a full-time controller and head of finance is appointed or until a mutually agreed written date. Compensation was adjusted from $25,000 to a monthly flat fee of $26,000. The company also reported Q1 2026 revenue of $34.5 million (above analyst expectations) but missed the EPS target; Neuronetics announced a partnership with ANT Neuro to integrate neuronavigation technology. » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde NEURONETICS INC. DL-,01 en omsætning på 36,42 mio. € og et nettoresultat på -3,01 mio. €

(EUR)	juni 2026	YoY
Omsætning	36,42 mio.	12,65 %
Bruttofortjeneste	18,6 mio.	23,43 %
Nettoresultat	-3,01 mio.	64,90 %
EBITDA	-2,38 mio.	60,86 %

Fundamentale data

Nøgletal	Værdi
Markedsværdi	182,31 mio. €
Antal aktier	69,59 mio.
Højeste/laveste i 52 uger	3,08 € - 0,69 €
Udbytte	Nej
Beta	1,17
P/E (PE Ratio)	-7,07
PEG (PEG Ratio)	-0,06
K/I (PB Ratio)	12,15
P/S (PS Ratio)	1,36

Virksomhedsprofil

Neuronetics, Inc. ist ein Medizintechnikunternehmen im kommerziellen Stadium, das Produkte für Patienten mit neurologischen Störungen in den Vereinigten Staaten und international entwickelt und vermarktet. Das Unternehmen bietet das NeuroStar Advanced Therapy System an, eine nicht-invasive und nicht-systemische Behandlung in der Praxis zur Behandlung erwachsener Patienten mit schweren depressiven Störungen. Das NeuroStar Advanced Therapy System nutzt die transkranielle Magnetstimulation, um ein gepulstes Magnetfeld von MRT-Stärke zu erzeugen, das elektrische Ströme induziert, die bestimmte Hirnregionen stimulieren, die mit der Stimmung in Verbindung stehen. Das Unternehmen vertreibt seine Produkte über sein Vertriebs- und Kundendienstteam an Psychiater. Neuronetics, Inc. wurde im Jahr 2001 gegründet und hat seinen Hauptsitz in Malvern, Pennsylvania.

Navn	NEURONETICS INC. DL-,01
CEO	Daniel L. Reuvers
Hjemsted	Malvern, pa USA
Websted	neurostar.com
Sektor	Cykliske forbrugsvarer
Branche	Forbrugsgoder
Børsnotering	28.06.2018
Medarbejdere	658